Artelo Biosciences (ARTL) said Monday that new preclinical data showed its drug candidate ART12.11 demonstrated antidepressant-like activity and cognitive benefits in a stress-induced depression model in rats.
The company said a 28-day regimen reversed depressive behaviors and improved cognitive function, performing comparably to the selective serotonin reuptake inhibitor Sertraline in behavioral measures.
ART12.11 also restored spatial and short-term memory deficits without negatively impacting social memory, according to the company.
The company's shares were up 179% in recent premarket activity on Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.